Mankind Pharma has released its investor presentation for the second quarter of fiscal year 2026. Revenue grew by 20.8%, driven by outperformance in Chronic and BSV consolidation. Domestic revenue increased by 15% year-over-year. The company expects growth recovery in H2. BSV growth initiatives are progressing well with double-digit sequential growth. Mankind Pharma continues to focus on steady base business, specialty chronic, OTC business, and BSV portfolio.
Q2 FY26 Financial Highlights
Mankind Pharma reported a revenue of ₹3,697 Cr for Q2 FY26, a 20.8% YoY growth. EBITDA stood at ₹924 Cr with a margin of 25.0%. The domestic business grew by 15% YoY. The company’s revenue increase was supported by outperformance in Chronic and BSV consolidation, though partially impacted by GST disruption.
Segmental Performance
Domestic business contributed 86% to the revenue, while exports accounted for 14%. Within the domestic segment, the domestic business (excluding consumer healthcare) contributed 93%, and consumer healthcare contributed the remaining 7%.
Key Growth Drivers
The company experienced continued outperformance in chronic growth, with Cardiac growing 1.3x and Anti-diabetes growing 1.2x. The Consumer Healthcare (OTC) segment was impacted due to heavy rains and GST 2.0, with growth expected to recover in H2.
Strategic Focus Areas
Mankind Pharma is focused on four key pillars: steady base business, fast-growing specialty chronic, high potential OTC business, and super specialty BSV portfolio. The company maintained its number one rank with a prescription share of 15.3%, and prescriber penetration increased by 30 bps to 84.2%.
ESG Initiatives
The company reported that 67.2% of treated waste water was recycled in H1 FY26, compared to 46.4% in H1 FY25. Renewable power constituted 92% of the total power usage. The company also saw a 9.3% YoY reduction in fresh water intensity.
BSV Integration
BSV’s super specialty portfolio integration is on track, and the integration with Mankind is progressing as planned.
Source: BSE
